<DOC>
	<DOCNO>NCT01330316</DOCNO>
	<brief_summary>The objective trial collect evidence safety efficacy 24 week treatment BI 201335 240 mg combination 24 48 week Pegylated Interferon ( PegIFN ) ribavirin ( RBV ) treatment experienced patient withdraw PegIFN RBV treatment due lack efficacy 1220.7 , 1220.30 1220.47 trial .</brief_summary>
	<brief_title>A Rollover Study BI 201335 Combination With Pegylated Interferon-alpha Ribavirin Treatment-experienced Genotype 1 Hepatitis C Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criterion : Chronic hepatitis C infection GT1 patient fail prior treatment PegIFN RBV 1220.7 , 1220.30 1220.47 trial BI 201335 Phase III program . 1 . Patients trial 1220.7 , 1220.30 1220.47 BI 201335 fail treatment PegIFN/RBV placebo group due protocoldefined criterion treatment failure ( i.e . either nonresponse treatment relapse end treatment [ EOT ] ) . 2 . Patients must receive least 4 week assign trial medication compliant study procedure . 3 . Female patient : document hysterectomy , ovary remove , document tubal ligation , postmenopausal last menstrual period least 12 month prior screen , childbearing potential negative serum pregnancy test screen Day 1 , , sexually active , agree use one appropriate medically accept method birth control date screen 7 month last dose RBV addition consistent correct use condom . Patients must agree breastfeed time date screen 7 month last dose RBV . Medically accept method contraception females trial ethinyl estradiolcontaining contraceptive , diaphragm spermicide substance , intrauterine device cervical cap . Male patient : document sterile , without pregnant female partner ( ) consistently correctly use condom female partner ( ) ( childbearing potential ) agree use one appropriate medically accept method birth control date screen 7 month last dose ribavirin . It responsibility male patient ensure partner ( ) pregnant prior screening study become pregnant treatment observation phase . Female partner childbearing potential must perform monthly pregnancy test date screen 7 month last dose ribavirin ( test provide sponsor ) . 4 . Signed informed consent form prior trial participation . Exclusion criterion : 1 . Evidence acute chronic liver disease due cause chronic HCV infection . Incidental steatosis diagnose biopsy exclusion criterion . 2 . HIV coinfection 3 . Hepatitis B virus ( HBV ) infection base presence HBsAg 4 . Active malignancy , history malignancy within last 5 year prior screen ( exception appropriately treat basal cell carcinoma skin situ carcinoma uterine cervix ) 5 . Active , history alcohol illicit drug abuse cannabis within past 12 month 6 . A condition define one opinion investigator may put patient risk participation study , may influence result study , limit patient ability participate study 7 . Usage investigational drug within 30 day prior screen , plan usage investigational drug course study . 8 . Received concomitant systemic antiviral , hematopoietic growth factor , immunomodulatory treatment within 30 day prior screen . Patients treat oral antiviral acyclovir , famciclovir valacyclovir recurrent herpes simplex infection ; oseltamivir zanamivir influenza A infection , may screen . 9 . Received silymarin ( milk thistle ) , glycyrrhizin , Shosaikoto ( SST ) within 28 day prior enrolment throughout treatment phase trial . 10 . Known hypersensitivity ingredient study drug . 11 . Alpha fetoprotein value &gt; 100 ng/mL screening ; &gt; 20 ng/mL = 100 ng/mL , patient may include evidence liver cancer appropriate imaging study ( e.g. , ultrasound , CT scan , MRI ) within last 6 month prior randomization ( Visit 2 ) . Other exclusion criterion relate pegylated interferon and/or ribavirin restriction list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>